Parelsnoer Institute Biobank Hereditary Colorectal Cancer: A Joint Infrastructure for Patient Data and Biomaterial on Hereditary Colorectal Cancer in the Netherlands

Each year approximately 15,000 patients are diagnosed with colorectal cancer (CRC) in the Netherlands, of whom 5–10% are associated with a hereditary syndrome. To enable future research into hereditary CRC, we established a collaborative biobank for hereditary CRC in all eight University Medical Centers (UMCs) in the Netherlands in 2009. This Biobank Hereditary CRC is part of the Parelsnoer Institute (PSI), which is funded by the Dutch Federation of UMCs and the Dutch Government. Besides the multicenter collaboration, the multidisciplinary nature of this biobank – involving Gastroenterology, G... Mehr ...

Verfasser: Peggy Manders
Janet R. Vos
Richarda M. de Voer
Liselot P. van Hest
Rolf Sijmons
Chantal V. Hoge
Fokke G. Terpstra
Manon C. Spaander
Wilma E. Mesker
Evelien Dekker
Nicoline Hoogerbrugge
Dokumenttyp: Artikel
Erscheinungsdatum: 2019
Reihe/Periodikum: Open Journal of Bioresources, Vol 6 (2019)
Verlag/Hrsg.: Ubiquity Press
Schlagwörter: Clinical biobanking / Parelsnoer Institute / hereditary colorectal cancer / harmonized standards / research standards / Medicine / R / Computer applications to medicine. Medical informatics / R858-859.7
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29171549
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.5334/ojb.54

Each year approximately 15,000 patients are diagnosed with colorectal cancer (CRC) in the Netherlands, of whom 5–10% are associated with a hereditary syndrome. To enable future research into hereditary CRC, we established a collaborative biobank for hereditary CRC in all eight University Medical Centers (UMCs) in the Netherlands in 2009. This Biobank Hereditary CRC is part of the Parelsnoer Institute (PSI), which is funded by the Dutch Federation of UMCs and the Dutch Government. Besides the multicenter collaboration, the multidisciplinary nature of this biobank – involving Gastroenterology, Genetics and Surgery – is essential for its functionality and value. Patients at increased risk of hereditary CRC and/or Polyposis, or with a proven germline mutation causing CRC and/or Polyposis are included. Both clinical data (demographic data, details on medical and family history, information on surveillance, endoscopy and surgery, results of microsatellite instability and molecular genetic tests) and biomaterial (DNA, plasma, serum and tissue) are collected in a standardized manner.